Responses
Oral Plenary
Plenary V
IGCS20_1207
18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.